Advances in Cancer Research - 1st Edition - ISBN: 9780128151273, 9780128151280

Advances in Cancer Research, Volume 138

1st Edition

Serial Volume Editors: Kenneth D. Tew Paul Fisher
eBook ISBN: 9780128151280
Hardcover ISBN: 9780128151273
Imprint: Academic Press
Published Date: 17th March 2018
Page Count: 248
Sales tax will be calculated at check-out Price includes VAT/GST
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
15% off
122.00
103.70
103.70
103.70
103.70
103.70
103.70
103.70
103.70
171.00
145.35
145.35
145.35
145.35
145.35
145.35
145.35
145.35
119.00
101.15
101.15
101.15
101.15
101.15
101.15
101.15
101.15
239.04
203.18
203.18
203.18
203.18
203.18
203.18
203.18
203.18
Unavailable
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  1. Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity
  2. Liliya Tyutyunyk-Massey, Syed Haqqani, Reshma Mandava, Kirubel Kentiba, Mallika Dammalapati, Nga Dao, Joshua Haueis, David Gewirtz and Joseph W. Landry

  3. VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation
  4. Diana Fang and Eduardo N. Maldonado

  5. Acquired Resistance to Drugs Targeting Tyrosine Kinases
  6. Steven A. Rosenzweig

  7. Extracellular Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes
  8. Scott T. Eblen

  9. Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases
  10. Mitchell E. Menezes, Praveen Bhoopathi, Anjan K. Pradhan, Luni Emdad, Swadesh K. Das, Chunqing Guo, Xiang-Yang Wang, Devanand Sarkar and Paul B. Fisher

  11. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
  12. Jesse J. McClure, Xiaoyang Li and C. James Chou

  13. Prospects of Gene Therapy to Treat Melanoma

Mitchell E. Menezes, Sarmistha Talukdar, Stephen L. Wechman, Swadesh K. Das, Luni Emdad, Devanand Sarkar and Paul B. Fisher


Description

Advances in Cancer Research, Volume 138, the latest release in this ongoing, well-regarded serial provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents original reviews on research bridging oncology and gene expression, with this volume covering unconventional approaches to modulating the immunogenicity of tumor cells, tumor dormancy and immunoediting, the emerging role of anti-apoptotic Bcl-2 family proteins in chemoresistance, Beclin-1 and autophagy, MDA-7/IL-24, and nanotechnology and medicine.

Key Features

  • Provides information on cancer research
  • Offers outstanding and original reviews on a range of cancer research topics
  • Serves as an indispensable reference for researchers and students alike

Readership

Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology


Details

No. of pages:
248
Language:
English
Copyright:
© Academic Press 2018
Published:
Imprint:
Academic Press
eBook ISBN:
9780128151280
Hardcover ISBN:
9780128151273

Ratings and Reviews


About the Serial Volume Editors

Kenneth D. Tew Serial Volume Editor

Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Affiliations and Expertise

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA

Paul Fisher Serial Volume Editor

Paul B. Fisher, M.Ph., Ph.D., is an accomplished molecular biologist investigating the mechanisms involved in cancer development and progression in order to define improved methods for cancer prevention, detection and therapy. Fisher pioneered a powerful technique to study gene expression in specific tissues or cell types known as subtraction hybridization, which he has used to identify genes involved in many important and medically relevant physiological processes including cancer, neurodegeneration and infectious diseases. Studies in his laboratory focus on understanding the molecular and biochemical reasons for cancer development with a specific focus on understanding how cancers spread, a process called metastasis. The ultimate aim is to use this collected knowledge to bring new, more effective prevention techniques, diagnostic approaches and therapies from the laboratory bench to the patient’s bedside. This is epitomized by his studies involving mda-7/IL-24, a gene that was discovered in his laboratory and has displayed significant clinical efficacy in a phase 1 clinical trial when injected directly into advanced cancers using a form of viral gene therapy. Using a novel cancer terminator virus, Ad.5/3-CTV, that is designed to replicate only within cancer cells while delivering the immune-modulating and toxic mda-7/IL-24 gene, Fisher and his clinical colleagues are developing a clinical trial in patients with glioblastoma multiforme, the most common and deadly form of brain cancer. Fisher has been consistently funded by the National Institutes of Health (NIH) over the past 35 years and is among the top 5 percent of NIH funded investigators during this period. He has published over 500 primary papers and reviews, served on numerous NIH study sections and government and private grant review panels and has over 55 issued patents. He is the recipient of multiple National Cancer Institute (NCI) Program Project Grants; investigator initiated R01 grants from the NIH, NCI and National Institute of General Medical Sciences (NIGMS); private foundation grants from the National Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation; and an Institutional Research and Academic Career Development Award from the NIH focusing on preparing students from groups underrepresented in the sciences for research careers. Fisher is Professor and Chair of the Department of Human and Molecular Genetics at the Virginia Commonwealth University (VCU) School of Medicine, Founding Director of the VCU Institute of Molecular Medicine and Thelma Newmeyer Corman Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey Cancer Center.

Affiliations and Expertise

VCU Institute of Molecular Medicine, VA, USA